Annovis Bio Inc. (ANVS) option IV into data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts ANVS Hot Sheet
Join SI Premium – FREE
Annovis Bio Inc. (NYSE: ANVS) 30-day option implied volatility is at 333; compared to its 52-week range of 21 to 333 into topline efficacy data for phase II/III study of buntanetap in patients with mild to moderate Alzheimer's disease is expected in April.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NOV Inc (NOV) spreader of November and February 16 calls
- PayPal (PYPL) call put ratio 1 call to 1.1 puts into quarter results
- Robinhood (HOOD) call put ratio 1.3 calls to 1 put into quarter results
Create E-mail Alert Related Categories
OptionsRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
